Patients undergoing PCI for acute MI complicated by cardiogenic shock (AMICS) had worse outcomes—including more mortality and bleeding—when their hemodynamic support during that hospitalization was ...
NEW ORLEANS – The Impella 5.0 and 5.5 left ventricular assist device failed to measure up on outcomes when used for high-risk patients undergoing ventricular tachycardia (VT) ablation therapies, ...
Another observational study has questioned whether Impella ventricular assist pumps (Abiomed) should be used in patients with acute myocardial infarction (MI) complicated by cardiogenic shock (CS), at ...
Please provide your email address to receive an email when new articles are posted on . In some analyses, percutaneous microaxial LVAD for cardiogenic shock was tied to worse outcomes vs. medical ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Abiomed announced a recall of its LVAD due to ...
As an example of how this technology might be used in future clinical practice, Abiomed has already trained an AI algorithm to predict the next five minutes of a patient’s arterial pressure based only ...
For some patients, a percutaneous left ventricular assist device (LVAD) may increase the risk of subsequent aortic regurgitation (AR), especially when there’s a need for longer support, new data ...
Impella 2.5, the main product for Danvers, MA-based Abiomed Inc., has received FDA premarket approval (PMA) for use in elective and urgent high-risk percutaneous coronary intervention (PCI) procedures ...
DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide left ventricular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results